IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted two more abbreviated new drug applications (ANDAs) to the US FDA.
“We are excited to announce that we successfully developed and submitted two more ANDAs. Our experienced team of development professionals is focused on our mission, to build a portfolio of topical drug products for IGI.”
IGI President and CEO Charlie Moore commented, "We are excited to announce that we successfully developed and submitted two more ANDAs. Our experienced team of development professionals is focused on our mission, to build a portfolio of topical drug products for IGI." The development of ANDA products has successfully been integrated into the Company's ongoing contract services business.
Cellular Origins, Fresenius Kabi sign development agreement for scalable automation of cell and gene therapy manufacturing